Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Assets (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Current Assets data on record, last reported at $272.4 million in Q3 2025.

  • For Q3 2025, Current Assets rose 7.42% year-over-year to $272.4 million; the TTM value through Sep 2025 reached $272.4 million, up 7.42%, while the annual FY2024 figure was $232.8 million, 8.09% up from the prior year.
  • Current Assets reached $272.4 million in Q3 2025 per STOK's latest filing, up from $270.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $375.7 million in Q1 2025 and bottomed at $193.3 million in Q1 2024.
  • Average Current Assets over 4 years is $264.0 million, with a median of $264.6 million recorded in 2022.
  • Peak YoY movement for Current Assets: decreased 28.48% in 2024, then surged 94.4% in 2025.
  • A 4-year view of Current Assets shows it stood at $244.1 million in 2022, then dropped by 11.77% to $215.3 million in 2023, then rose by 8.09% to $232.8 million in 2024, then increased by 17.05% to $272.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $272.4 million in Q3 2025, $270.0 million in Q2 2025, and $375.7 million in Q1 2025.